Statement on Seasonal Influenza Vaccine for 2011–2012

doi:10.14745/ccdr.v37i00a05

Cited by 13 publications

(1 citation statement)

References 162 publications

(153 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For public health program-level decision making (i.e. provinces/territories making decisions for publicly funded immunization programs), NACI recommends that any of the available influenza vaccines be used, as there is insufficient evidence (cost-effectiveness assessments have not been performed) to make comparative public health program-level recommendations on the use of the available vaccines Abbreviations: IIV3-Adj, adjuvanted trivalent inactivated influenza vaccine; IIV3-HD, high-dose trivalent inactivated influenza vaccine; IIV3-SD, standard-dose trivalent inactivated influenza vaccine; IIV4-SD, standard-dose quadrivalent inactivated influenza vaccine; LAIV4, quadrivalent live attenuated influenza vaccine; -, not applicable a Agriflu (six months and older), Fluviral (six months and older), Influvac (three years and older) b Afluria Tetra (five years and older), Flulaval Tetra (six months and older), Fluzone Quadrivalent (six months and older) c Fluad Pediatric (6-23 months) or Fluad (65 years and older) d Fluzone High-Dose (65 years and older) e FluMist Quadrivalent (2-59 years) f Evidence suggests moderate improvement in antibody response in infants, without an increase in reactogenicity, with the use of full vaccine doses (0.5 mL) for unadjuvanted inactivated influenza vaccines (9,10). This moderate improvement in antibody response without an increase in reactogenicity is the basis for the full dose recommendation for unadjuvanted inactivated vaccine for all ages.…”

Section: Iiv4-sdmentioning

confidence: 99%

Summary of the NACI Seasonal Influenza Vaccine Statement for 2019–2020

Zhao

Young

Gemmill

2019

CCDR

View full text Add to dashboard Cite

Background: Many different influenza vaccines are authorized for use in Canada and new evidence on influenza and vaccines is continually emerging. The National Advisory Committee on Immunization (NACI) provides annual recommendations regarding the use of seasonal influenza vaccines to the Public Health Agency of Canada (PHAC) for the upcoming influenza season. Objective: To summarize NACI recommendations regarding the use of seasonal influenza vaccines for the 2019-2020 influenza season, including conclusions from reviews of evidence on 1) a new split virus quadrivalent inactivated influenza vaccine and 2) the comparative effectiveness and immunogenicity of subunit and split virus inactivated influenza vaccines in adults 65 years of age and older. Methods: For both topics, the NACI Influenza Working Group developed a predefined search strategy to identify all eligible studies, assessed their quality, summarized and analyzed the findings and, according to the NACI evidence-based process, proposed recommendations and identified the grade of evidence that supported them. In light of the evidence, the recommendations were then considered and approved by NACI. Results: NACI concluded that the new split virus quadrivalent inactivated influenza vaccine has a safety and immunogenicity profile comparable to the quadrivalent inactivated influenza vaccines already authorized for adults and children 5 years of age and older (Grade B Evidence). Therefore, NACI recommended that this new vaccine may be considered among the quadrivalent inactivated influenza vaccines offered to adults and children five years of age and older (Discretionary NACI Recommendation). However, NACI concluded that the evidence is not sufficient (Grade I Evidence) to support specific recommendations on the differential use of subunit and split virus inactivated influenza vaccines in adults 65 years of age and older. Conclusion: NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually to anyone six months of age and older who does not have contraindications to the vaccine, with focus on the groups for whom influenza vaccination is particularly recommended. This includes people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk, people who provide essential community services and people in direct contact with poultry infected with avian influenza during culling operations.

show abstract

Section: Iiv4-sdmentioning

confidence: 99%

Summary of the NACI Seasonal Influenza Vaccine Statement for 2019–2020

Zhao

Young

Gemmill

2019

CCDR

View full text Add to dashboard Cite

show abstract

Determinants of 2009 A/H1N1 Influenza Vaccination Among Pregnant Women in Hong Kong

Tarrant¹,

Wu²,

Yuen³

et al. 2012

Matern Child Health J

View full text Add to dashboard Cite

During the 2009–2010 A/H1N1 influenza pandemic, pregnant women infected with the virus experienced excess morbidity and mortality when compared with other groups. Once a vaccine was available, pregnant women were a priority group for vaccination. Only a few studies have reported on the uptake of 2009 A/H1N1 influenza vaccine among pregnant women during the pandemic and none were from Asia. The purpose of this study was to examine factors associated with 2009 A/H1N1 influenza vaccine uptake among pregnant women in Hong Kong. Using a multi-center, cross-sectional design, we recruited 549 postpartum women from four post-natal wards in Hong Kong over a 4-month period during the second wave of the A/H1N1 influenza pandemic in the winter and spring of 2010. Only 6.2% (n = 34) of participants had received the 2009 A/H1N1 influenza vaccine and 4.9% (n = 27) had received the seasonal influenza vaccine. The most common reasons for not receiving the 2009 A/H1N1 vaccine were fear of causing harm to themselves or their fetus. A high knowledge level (OR = 19.06; 95% CI 5.55, 65.48), more positive attitudes (OR = 3.52; 95% CI 1.37, 9.07), and having a family member who had the 2009 A/H1N1 influenza vaccine (OR = 7.69; 95% CI 2.92, 20.19) were independently and positively associated with vaccination. Study results show an unacceptably low uptake of the pandemic A/H1N1 influenza vaccine among pregnant women in Hong Kong. Interventions to increase influenza vaccine knowledge and uptake among this group should be a priority for future pandemic planning and seasonal vaccination campaigns.

show abstract